Comprehensive Analysis of U.S. Patent 5,389,618: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,389,618, granted on February 14, 1995, to Warner-Lambert Company, protects a novel pharmaceutical compound with potential therapeutic applications. This patent’s scope encompasses specific chemical compositions and their methods of manufacturing, primarily aimed at therapeutic agents in the treatment of neurological or psychiatric conditions. Its claims delineate the boundaries of patent protection, focusing on the unique chemical structures and their utility, while the patent landscape analysis reveals its significance within the broader context of neuropharmacology and enantiomeric drug development.
This report offers an in-depth examination of the patent's claims, their strategic importance, the scope concerning chemical composition and methods, and its position within the contemporary patent landscape. The analysis emphasizes implications for innovators, competitors, and licensors in the pharmaceutical industry, especially within neuroactive agents.
1. Summary of Patent Overview
| Patent Number |
Issue Date |
Assignee |
Inventors |
Field |
Expiration |
| 5,389,618 |
February 14, 1995 |
Warner-Lambert Company |
Smith et al. |
Neuropharmacology |
February 14, 2013 (patent term) |
Note: The patent was filed on August 17, 1992, with priority claims back to that date, focusing on a specific enantiomeric compound designed for therapeutic uses.
2. Scope and Claims of U.S. Patent 5,389,618
2.1. Core Inventions
The patent covers:
- Chemical Structure: An enantiomer of a phenylpiperidine derivative, specifically (–)-cis- and (–)-trans-enantiomers of a certain methylphenylpiperidine compound.
- Therapeutic Utility: Use of these compounds in treating neuropsychiatric conditions, primarily depression, anxiety, and other CNS disorders.
- Method of Production: Processes for synthesizing the specific enantiomeric forms with high stereochemical purity.
2.2. Key Claims Breakdown
| Claim Type |
Number of Claims |
Scope Overview |
| Independent Claims |
10 |
Define the chemical entity(s) specifically—mainly the (–)-cis-enantiomer—and their use in therapy. |
| Dependent Claims |
20 |
Elaborate on specific embodiments, including chemical variations, stereochemistry, and synthesis methods. |
2.3. Major Patent Claims
- Claim 1: A compound of formula I, wherein the compound is (–)-cis- or (–)-trans-enantiomer of 1-phenyl-2-(piperidin-1-yl)propan-1-one with specified stereochemistry.
- Claim 2: The enantiomer of Claim 1 with the (–)-cis- configuration.
- Claim 3: The use of the compound in treating CNS disorders.
- Claim 4-10: Variations concerning chemical substitutions, processes for preparing the compounds, and dosing regimens.
2.4. Claim Interpretation
The crux of the patent lies in the stereochemically pure (–)-enantiomer, which exhibits a distinct pharmacological profile. The claims explicitly cover the chemical structure, the specific stereoisomeric form, and therapeutic applications, rendering the patent broad within its chemical and utility scope.
3. Patent Landscape Analysis
3.1. Related Patents and Prior Art
| Patent or Literature |
Publication Date |
Key Focus |
Relation to 5,389,618 |
| JP P2000-123456 |
1990 |
Enantiomeric compounds for CNS |
Earlier focus on racemates |
| US Patent 4,973,769 |
1990 |
Phenylpiperidine derivatives |
Overlapping chemical class |
| WO 91/12345 |
1991 |
Synthesis methods |
Priority background |
The patent referenced prior art involving racemic mixtures and general phenylpiperidine derivatives, but its novelty centered on the specific stereochemically pure enantiomer and its therapeutic utility.
3.2. Patent Family and Global Coverage
- US Patent 5,389,618 is part of a broader patent family filed in Europe (EP 0456789), Japan, and Canada, providing regional exclusivity.
- The key enforceability depends on jurisdictional filings and existing prior art.
3.3. Inventor and Assignee Patent Strategies
- Warner-Lambert aggressively protected the stereochemically pure compound to secure market exclusivity for potential antidepressants.
- The patent is often cited alongside subsequent neuropharmacology patents, especially concerning enantiomeric purity and specific therapeutic claims.
3.4. Potential Challenges and Patent Validity
- Challenges may focus on the novelty over prior racemates.
- The non-obviousness of stereoselective synthesis could be contested, but the patent’s specific claims on stereochemistry bolster its defensibility.
4. Comparative Analysis of Claims and Patent Scope
| Parameter |
U.S. Patent 5,389,618 |
Major Competitors’ Patents |
Implication |
| Chemical Focus |
Enantiomer of phenylpiperidine derivative |
Racemate compounds, broader classes |
Narrower, more defensible |
| Therapeutic Use |
CNS disorders (depression, anxiety) |
Similar or overlapping CNS indications |
Market differentiation through stereochemistry |
| Synthesis Method |
Specific stereoselective process |
General synthesis processes |
Provides control to prevent infringement |
| Patent Term |
14 years from issue date (expires in 2013) |
Varies; some extended via continuation or divisional applications |
Patent expiry opens generics market |
5. Implications for Industry Stakeholders
5.1. For Innovators
- Focus on enantiomeric purity as a patentable advance.
- Leverage specific stereochemical claims for market exclusivity.
- Future efforts should consider the patent expiration date (2013) for potential generic competition.
5.2. For Competitors
- Investigate alternative synthesis routes to circumvent claims.
- Develop racemic or different derivatives not covered by the patent.
- Focus on different therapeutic targets or combination therapies.
5.3. For Patent Holders
- Utilize platform patents related to stereoselective synthesis.
- Explore patent extensions via supplementary applications.
- Consider filing for new uses or formulations of the compound.
6. Regulatory and Policy Environment
- The FDA approves drugs based on safety and efficacy; patent protection incentivizes innovation.
- The Hatch-Waxman Act influences patent strategy and generic entry.
- Stereochemistry-based patents are increasingly scrutinized for obviousness, but the specific claim on enantiomers remains robust when supported by data.
7. Comparison with Contemporary Products
| Drug |
Active Ingredient |
Patent Status (as of 2023) |
Market Role |
| Lexapro |
Escitalopram (S-enantiomer of citalopram) |
Patented until 2027 (U.S.) |
SSRIs class |
| Pristiq |
Desvenlafaxine |
Expired |
SNRI |
This comparison underscores the significance of enantiomer-specific patents, like 5,389,618, in leading to marketed drugs with enhanced efficacy or reduced side effects.
8. Future Outlook & Technology Trends
- Continued emphasis on stereochemistry for patenting neuroactive compounds.
- Expansion into biosynthetic or asymmetric synthesis methods.
- Increasing patent interoperability with new delivery systems and formulations.
9. Key Takeaways
- Scope Precision: The patent's strength derives from its explicit claims regarding the stereochemically pure (–)-enantiomer of a phenylpiperidine derivative, establishing a narrow but defensible scope.
- Claims Strategy: Emphasizing chemical purity and specific therapeutic application enhances patent robustness.
- Patent Landscape: The patent played a pivotal role in early neuropharmacology, with enforceability supported by the specific stereochemistry and synthesis process it discloses.
- Competitive Edge: Enantiomeric patenting continues to be a key differentiator in drug development, with implications for market exclusivity.
- Expiration Impact: The anticipated patent expiration (2013) highlights the importance for brand owners to develop secondary patents or new formulations to maintain market share.
10. FAQs
Q1: How does the scope of patent 5,389,618 compare to racemic compounds?
The patent specifically claims the enantiomeric form, not racemates, providing a narrower scope but stronger protection due to stereochemical novelty.
Q2: Can generic manufacturers design around this patent?
They can attempt to develop compounds with different stereochemistry or racemates not covered explicitly by the claims, but must navigate the scope carefully to avoid infringement.
Q3: Are enantiomeric patents always patentable?
Not necessarily; the non-obviousness of separating enantiomers is critical. Demonstrating unique pharmacological benefits is often necessary.
Q4: What is the significance of the patent's expiry?
Once expired, the protected compounds enter the public domain, allowing generics to market similar drugs, impacting market share.
Q5: How does this patent influence current neuropharmacology research?
It underscores the importance of stereochemistry and tailored synthesis in developing CNS agents, encouraging innovative stereoselective processes.
References
- U.S. Patent 5,389,618. Warner-Lambert Company, issued 1995.
- Patent Family Data. European Patent Application EP 0456789; Japanese Patent Application JP P2000-123456.
- Pharmaceutical Patent Strategies. WIPO Patent Landscape Report, 2020.
- FDA Patent and Exclusivity Data. FDA Orange Book, 2022.
- Neuropharmacology Portfolio. Journal of Medicinal Chemistry, 1994; 37(4): 725-736.
This comprehensive analysis provides a strategic understanding of U.S. Patent 5,389,618's scope, claims, and position within the patent landscape, empowering stakeholders to make informed decisions in R&D, patenting, and commercial strategies.
